SequelSEC

aTYR PHARMA INC ATYR

Biological Products, (No Diagnostic Substances) · CIK 0001339970 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$190.00K
Fiscal year ended 2025-12-31
Operating income
-$77.63M
Fiscal year ended 2025-12-31
Free cash flow
-$62.06M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$463.82MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$4.73Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2441.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity6.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin-32664.7%3th
R&D / revenue31694.2%96th
Operating margin-40856.3%4th
Net margin-39009.5%4th
CapEx / revenue40.5%82th
Revenue YoY growth-19.1%32th
Current ratio5.30x55th

aTYR PHARMA INC (ATYR) reported revenue of $190.00K and net income of -$74.12M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from aTYR PHARMA INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

aTYR PHARMA INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$190.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$77.63M
Net income-$74.12M
Research & development$60.22M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$17.60M
Selling & marketingUnavailable

Balance

aTYR PHARMA INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$10.74M
Total assets$93.00M
Current assets$80.24M
Total liabilitiesUnavailable
Current liabilities$15.15M
Total equity incl. NCI$67.29M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.89M

Cash flow

aTYR PHARMA INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$61.99M
Capital expenditures$77.00K
Investing cash flow-$5.05M
Financing cash flow$66.01M
Net change in cash-$1.03M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$664.00K

Derived

aTYR PHARMA INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$62.06M
Gross marginUnavailable
Operating margin-40856.3%
FCF margin-32664.7%
SBC / revenueUnavailable
Current ratio5.30x
Revenue YoY growth-19.1%
Net margin-39009.5%
R&D / revenue31694.2%
CapEx / revenue40.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATYR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.